NCT03059485 - DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

December 4, 2023

Study Completion Date

September 23, 2024

Conditions

Acute Myelogenous Leukemia

Interventions

BIOLOGICAL

DC/AML Fusion Vaccine

The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells

OTHER

Observation

Traditional care provided by the hospital.

Trial Locations (4)

University of Wisconsin Carbone Cancer Center, Madison

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston